Table 1 The detailed clinical information of all included samples
From: Identification and validation of a five-gene prognostic signature for hepatocellular carcinoma
| Â | TCGA | ICGC |
|---|---|---|
Survival status | ||
 Alive | 224 | 187 |
 Dead | 119 | 41 |
Age | ||
 ≤ 65 | 127 | 88 |
 > 65 | 216 | 140 |
Gender | ||
 Male | 233 | 167 |
 Female | 110 | 61 |
Stage | ||
 I–II | 238 | 140 |
 III–IV | 83 | 88 |
Prior malignancy | ||
 Yes | 31 | 29 |
 No | 312 | 199 |
Grade | ||
 G1 | 53 |  |
 G2 | 161 |  |
 G3–4 | 124 |  |
BMI | ||
 ≤ 25 | 163 |  |
 > 25 | 153 |  |
AFP | ||
 ≤ 300 ng/ml | 197 |  |
 > 300 ng/ml | 62 |  |
New tumor event after initiate treatment | ||
 Yes | 168 |  |
 No | 162 |  |
Cancer status | ||
 With tumor | 149 |  |
 Tumor free | 179 |  |
Vascular tumor cell type | ||
 None | 188 |  |
 Micro and marco | 101 |  |
Race | ||
 White | 169 |  |
 Others | 164 |  |
Additional_pharmaceutical_therapy | ||
 No | 108 |  |
 Ye | 29 |  |
Residual_tumor | ||
 R0 | 303 |  |
 R1–2 | 16 |  |
ARID1A | ||
 Mutation | 25 | 23 |
 Wild | 306 | 203 |